Nuevos anticoagulantes orales

• Alejandro Berkovits ^[1] ; Andrés Aizman ^[1] ; Pamela Zúñiga ^[1] ; Jaime Pereira ^[1] ; Diego Mezzano ^[1]
  1. [1] Pontificia Universidad Católica de Chile

     Pontificia Universidad Católica de Chile

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 139, Nº. 10, 2011, págs. 1347-1355
• Idioma: español
• Títulos paralelos:
  • New oral anticoagulant drugs
• Enlaces
  • Texto completo
• Resumen

  • Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the most commonly used. In the last five years several new drugs for long term anticoagulation have been developed, which can inhibit single clotting factors with the purpose of improving drug therapeutic range and, ideally, minimizing bleeding risks. This review addresses the state of the art on the clinical use of inhibitors of activated factor X and thrombin.